Aktie A141080 LIGACHEM BIOSCIENCES INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen LigaChem Biosciences Inc.

Aktien

A141080

KR7141080002

A141080

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 14.05.2024 		% 5 Tage % 1. Jan.
65 700 KRW -1,20 % Intraday Chart für LigaChem Biosciences Inc. -4,23 % +1,08 %
08.04. NextCure, Inc. und LigaChem Biosciences, Inc. präsentieren präklinische Daten zu B7-H4-Antikörper-Wirkstoffkonjugat auf der AACR 2024 CI
29.03. Pan Orion Corp. Ltd. hat die Übernahme von 4,93% der Anteile an LegoChem Biosciences, Inc. (KOSDAQ:A141080) von Kim Yong Ju und Park Se Jin abgeschlossen. CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024
Pan Orion Corp. Ltd. completed the acquisition of 4.93% stake in LegoChem Biosciences, Inc. from Kim Yong Ju and Park Se Jin.
LegoChem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Samsung Biologics Collaborates with LegoChem Biosciences on ADC Development and Manufacturing
Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing
Orion Set to Acquire 25% Stake in LegoChem Biosciences
South Korean Shares Close Lower Amid Geopolitical Tension
Legochem Biosciences to Raise 469.8 Billion Won through Rights Issue; Shares Fall 5%
LegoChem Biosciences, Inc. announced that it expects to receive KRW 1018.327793998 billion in funding from Pan Orion Corp. Ltd.
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.
LegoChem Biosciences, Inc.'s Equity Buyback announced on June 28, 2023, has expired with 140,000 shares, representing 0.53% for KRW 4,879.08 million.
J&J : accord de licence avec le coréen LegoChem dans les ADC
Legochem Biosciences Announces License Agreement for Lcb84 Trop2-Targeted ADC
LegoChem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial
BostonGene and LegoChem Biosciences, Inc. Announce Collaboration to Support Phase I/II Study of LCB84, TROP2-Directed ADC, in Patients with Advanced Cancers
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.
Bridge Biotherapeutics, Inc. announced that it has received KRW 5.9999904 billion in funding from LegoChem Biosciences, Inc.
Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 5.9999904 billion in funding from LegoChem Biosciences, Inc.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A141080 Aktie
  4. Nachrichten LigaChem Biosciences Inc.
  5. Andere Sprachen